Cargando…

Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma

Monoclonal antibodies (mAbs) directed against antigen-specific of multiple myeloma (MM) cells have Fc-dependent immune effector mechanisms, such as complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP), but the c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Romano, Alessandra, Storti, Paola, Marchica, Valentina, Scandura, Grazia, Notarfranchi, Laura, Craviotto, Luisa, Di Raimondo, Francesco, Giuliani, Nicola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8297441/ https://www.ncbi.nlm.nih.gov/pubmed/34307150 http://dx.doi.org/10.3389/fonc.2021.684561

Ejemplares similares

Role of Galectins in Multiple Myeloma
por: Storti, Paola, et al.
Publicado: (2017)

Neurofibromatosis type I and multiple myeloma coexistence: A possible link?
por: Accardi, Fabrizio, et al.
Publicado: (2018)

Role of 1q21 in Multiple Myeloma: From Pathogenesis to Possible Therapeutic Targets
por: Burroughs Garcìa, Jessica, et al.
Publicado: (2021)

Metabolic features of myeloma cells in the context of bone microenvironment: Implication for the pathophysiology and clinic of myeloma bone disease
por: Raimondi, Vincenzo, et al.
Publicado: (2022)

PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients
por: Costa, Federica, et al.
Publicado: (2021)

Molecular Features of the Mesenchymal and Osteoblastic Cells in Multiple Myeloma
por: Iannozzi, Nicolas Thomas, et al.
Publicado: (2022)

PD-L1/PD-1 Axis in Multiple Myeloma Microenvironment and a Possible Link with CD38-Mediated Immune-Suppression
por: Costa, Federica, et al.
Publicado: (2021)

Application of Next-Generation Sequencing for the Genomic Characterization of Patients with Smoldering Myeloma
por: Manzoni, Martina, et al.
Publicado: (2020)

Novel Approaches to Improve Myeloma Cell Killing by Monoclonal Antibodies
por: Storti, Paola, et al.
Publicado: (2020)

Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma
por: Dalla Palma, Benedetta, et al.
Publicado: (2020)

Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties
por: Costa, Federica, et al.
Publicado: (2017)

P58 LOW CD38 EXPRESSION BY PLASMA CELLS IN EXTRAMEDULLARY DISEASE IN MULTIPLE MYELOMA PATIENTS
por: Notarfranchi, L., et al.
Publicado: (2023)

Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response
por: Storti, Paola, et al.
Publicado: (2022)

Oncolytic Virotherapy and Microenvironment in Multiple Myeloma
por: Marchica, Valentina, et al.
Publicado: (2021)

Preclinical evidence of a direct pro-survival role of arginine deprivation in multiple myeloma
por: Trudu, Matteo, et al.
Publicado: (2022)

Label-Free Enrichment of Circulating Tumor Plasma Cells: Future Potential Applications of Dielectrophoresis in Multiple Myeloma
por: Musso, Nicolò, et al.
Publicado: (2022)

Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens
por: Botta, Cirino, et al.
Publicado: (2021)

PB2093: OVERALL SURVIVAL IN RELAPSED-REFRACTORY MYELOMA PATIENTS DEPENDS ON CIRCULATING PLASMA CELLS QUANTITATION
por: Parrinello, Nunziatina Laura, et al.
Publicado: (2023)

Mitochondrial Bioenergetics at the Onset of Drug Resistance in Hematological Malignancies: An Overview
por: Barbato, Alessandro, et al.
Publicado: (2020)

Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy
por: Marchica, Valentina, et al.
Publicado: (2020)

P830: IDENTIFICATION OF NOVEL TARGET GENES CORRELATED WITH 1Q21 AMPLIFICATION IN PATIENTS WITH SMOLDERING MYELOMA AND MULTIPLE MYELOMA
por: Thomas Iannozzi, Nicolas, et al.
Publicado: (2023)

P850: THE HUMORAL AND CELLULAR RESPONSE TO SARS-COV-2 MRNA VACCINATION IN PATIENTS WITH MULTIPLE MYELOMA AND PRE-MALIGNANT MONOCLONAL GAMMOPATHIES: IMPACT OF OMICRON VARIANT
por: Storti, P., et al.
Publicado: (2022)

Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimab
por: Duminuco, Andrea, et al.
Publicado: (2023)

How we manage smoldering multiple myeloma
por: Romano, Alessandra, et al.
Publicado: (2020)

Salvage Therapy of Multiple Myeloma: The New Generation Drugs
por: Romano, Alessandra, et al.
Publicado: (2014)

P01: ARGININE STARVATION IN MULTIPLE MYELOMA MICROENVIRONMENT CONVEYS BORTEZOMIB REFRACTORINESS VIA TLR4 PATHWAY.
por: Romano, A, et al.
Publicado: (2022)

Immunological Dysregulation in Multiple Myeloma Microenvironment
por: Romano, Alessandra, et al.
Publicado: (2014)

Lactate trafficking inhibition restores sensitivity to proteasome inhibitors and orchestrates immuno‐microenvironment in multiple myeloma
por: Barbato, Alessandro, et al.
Publicado: (2023)

Bone Marrow CX3CL1/Fractalkine is a New Player of the Pro-Angiogenic Microenvironment in Multiple Myeloma Patients
por: Marchica, Valentina, et al.
Publicado: (2019)

P855: FERROPTOSIS AS A NEW BCMA-TARGETED IMMUNOTHERAPY OFF-TARGET EFFECT IN MULTIPLE MYELOMA
por: La Spina, Enrico, et al.
Publicado: (2023)

Bispecific antibodies in multiple myeloma treatment: A journey in progress
por: Cho, Shih-Feng, et al.
Publicado: (2022)

P43 CIRCULATING CLONAL PLASMA CELLS AT START OF SALVAGE REGIMEN PROVIDE POWERFUL PROGNOSTICATION BIOMARKER IN MULTIPLE MYELOMA PATIENTS AT FIRST RELAPSE
por: Romano, A., et al.
Publicado: (2023)

A personalized molecular approach in multiple myeloma: the possible use of RAF/RAS/MEK/ERK and BCL-2 inhibitors
por: Raimondi, Vincenzo, et al.
Publicado: (2022)

Actionable Strategies to Target Multiple Myeloma Plasma Cell Resistance/Resilience to Stress: Insights From “Omics” Research
por: Manni, Sabrina, et al.
Publicado: (2020)

A rare case of multiple myeloma with intracranial extramedullary relapse: One or more myeloma clones?
por: Markovic, Uros, et al.
Publicado: (2019)

Phase II Trial of Maintenance Treatment With IL2 and Zoledronate in Multiple Myeloma After Bone Marrow Transplantation: Biological and Clinical Results
por: Fazzi, Rita, et al.
Publicado: (2021)

Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor
por: Sgherza, Nicola, et al.
Publicado: (2021)

Experts’ consensus on the definition and management of high risk multiple myeloma
por: Marcon, Chiara, et al.
Publicado: (2023)

Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey
por: Markovic, Uros, et al.
Publicado: (2021)

P870: DEFINING A NOVEL FUNCTION FOR THE POST-TRANSLATIONAL MODIFICATION UFMYLATION IN THE ADAPTIVE RESPONSE TO ARGININE DEPRIVATION IN MULTIPLE MYELOMA
por: Romano, A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qqnf45bu345k8ecce51qf7kf6f